{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-043098","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2023-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.920315+00:00","generated_at":"2026-06-07T20:11:37.923851+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protagenic Therapeutics receives Nasdaq minimum bid price deficiency notice","bullets":["Nasdaq notified PTIX on Nov 21, 2023 that common stock failed to maintain $1.00 minimum bid price for 30 consecutive business days.","Company has 180 calendar days, until May 19, 2024, to regain compliance with bid price requirement.","To regain compliance, closing bid price must be at least $1.00 for ten consecutive business days.","If not cured by May 19, 2024, PTIX may be eligible for an additional 180-day period if it meets other listing standards.","Stock continues trading on Nasdaq Capital Market under symbol PTIX; no immediate delisting effect."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-043098","json":"https://secwatch.observer/filing/0001493152-23-043098.json","markdown":"https://secwatch.observer/filing/0001493152-23-043098.md","text":"https://secwatch.observer/filing/0001493152-23-043098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000149315223043098/0001493152-23-043098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000149315223043098/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:11:37.923851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5074059f1c0ed7c809eb048c0bff488f5b9bbb9","claim":"Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"November 21, 2023, Protagenic Therapeutics, Inc. (“the Company”) received a deficiency letter (the “Notification Letter”) from the Nasdaq Listing Qualifications (“Nasdaq”) stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315223043098/0001493152-23-043098-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}